Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial

Blood (2017) 130 (Supplement 1): 4533.

https://doi.org/10.1182/blood.V130.Suppl_1.4533.4533

Published: 2017

Journal Articles

Treatment with the Novel TOPK Inhibitor OTS514 Exhibits Potent Anti-Myeloma Activity in Pre-Clinical Models

Andrew Stefka, MS, David Johnson, Shaun Rosebeck, PhD, Jae-Hyun Park, DVM, PhD, Yusuke Nakamura, MD, Andrzej J. Jakubowiak, MD

Blood (2017) 130 (Supplement 1): 4415.

https://doi.org/10.1182/blood.V130.Suppl_1.4415.4415

Published: 2017

Journal Articles

Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor Gs-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Previously Treated, Indolent Non-Hodgkin Lymphoma: Results From a Phase I Study

Nathan H Fowler, MD, Sven de Vos, MD, PhD, Marshall T. Schreeder, MD, John P. Leonard, MD, Ian W. Flinn, MD, PhD, Steve Coutre, MD, Nina D. Wagner-Johnston, MD, Jeff Sharman, MD, Ralph V. Boccia, MD, Jacqueline C. Barrientos, MD, Thomas E. Boyd, MD, Leanne M. Holes, Brian J. Lannutti, PhD, David Johnson, Thomas M. Jahn, MD/PhD, Langdon L Miller, MD, Wayne R Godfrey, MD

Blood (2012) 120 (21): 3645.

https://doi.org/10.1182/blood.V120.21.3645.3645

Published: 2012

Journal Articles

CAL-101 (GS-1101), a Specific Inhibitor of Phosphatidylinositol-3-Kinase-Delta (PI3Kδ), Disrupts Signals From the Microenvironment, Induces Apoptosis, and Enhances the Antitumor Activity of Everolimus (RAD001), An Inhibitor of Mammalian Target of Rapamycin (mTOR), in Mantle Cell Lymphoma (MCL),

Sarah A Meadows, Adam Kashishian, David Johnson, Roger G Ulrich, Langdon L Miller, Brian J. Lannutti, PhD

Blood (2011) 118 (21): 3730.

https://doi.org/10.1182/blood.V118.21.3730.3730

Published: 2011

Journal Articles

Exome Sequencing of the t(4;14) and t(11;14) Translocation Specific Subgroups of MM

Christopher P Wardell, PhD, Brian A Walker, PhD, David Johnson, PhD, Iwanka Kozarewa, PhD, Kerry Fenwick, Chris Lord, PhD, Alan Ashworth, PhD, FRS, Faith E Davies, MD, Gareth J Morgan, MD PhD

Blood (2011) 118 (21): 1817.

https://doi.org/10.1182/blood.V118.21.1817.1817

Published: 2011

Journal Articles

A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Jeff Sharman, MD, Sven de Vos, MD, PhD, John P. Leonard, MD, Richard R. Furman, MD, Steven E. Coutre, MD, Ian W. Flinn, MD, PhD, Marshall T. Schreeder, Jaqueline C. Barrientos, MD, Nina D. Wagner-Johnston, Thomas Boyd, MD, Nathan H. Fowler, MD, Leanne Holes, Brian Lannutti, David Johnson, Thomas M. Jahn, Langdon L Miller

Blood (2011) 118 (21): 1787.

https://doi.org/10.1182/blood.V118.21.1787.1787

Published: 2011

Journal Articles

Immunosuppression (IST) Can Be Safely Ceased during Chemotherapy for PTLD in Renal Transplant Patients.

Peter Mollee, MBBS, Matthew Hourigan, MBBS, David Johnson, MBBS, Mark Jones, BSc, Nikki Isbel, MBBS, Carmel Hawley, MBBS, Paula Marlton, MBBS, Maher Gandhi, MBBS, Scott Campbell, MBBS, Devinder Gill, MBBS

Blood (2007) 110 (11): 1366.

https://doi.org/10.1182/blood.V110.11.1366.1366

Published: 2007

Journal Articles

SNP Genotypes as Prognostic Factors Associated with Staging in Myeloma: The First Combined SNP Association Analysis of SWOG, ECOG, and MRC Clinical Trials from the Bank on a Cure.

Brian Van Ness, John Crowley, Emily Blood, Erik Rasmussen, Christine Ramos, Suzanne Grindle, Gareth Morgan, David Johnson, Antje Hoering, Philip Greipp, Bart Barlogie, Brian Durie

Blood (2005) 106 (11): 3489.

https://doi.org/10.1182/blood.V106.11.3489.3489

Published: 2005

NARROW

High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial

Treatment with the Novel TOPK Inhibitor OTS514 Exhibits Potent Anti-Myeloma Activity in Pre-Clinical Models

Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor Gs-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Previously Treated, Indolent Non-Hodgkin Lymphoma: Results From a Phase I Study

CAL-101 (GS-1101), a Specific Inhibitor of Phosphatidylinositol-3-Kinase-Delta (PI3Kδ), Disrupts Signals From the Microenvironment, Induces Apoptosis, and Enhances the Antitumor Activity of Everolimus (RAD001), An Inhibitor of Mammalian Target of Rapamycin (mTOR), in Mantle Cell Lymphoma (MCL),

Exome Sequencing of the t(4;14) and t(11;14) Translocation Specific Subgroups of MM

A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Immunosuppression (IST) Can Be Safely Ceased during Chemotherapy for PTLD in Renal Transplant Patients.

SNP Genotypes as Prognostic Factors Associated with Staging in Myeloma: The First Combined SNP Association Analysis of SWOG, ECOG, and MRC Clinical Trials from the Bank on a Cure.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only